Briggs Morrison Buys 20,400 Shares of Syndax Pharmaceuticals Inc (SNDX) Stock
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) CEO Briggs Morrison bought 20,400 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were purchased at an average cost of $7.46 per share, with a total value of $152,184.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of SNDX opened at $7.53 on Thursday. Syndax Pharmaceuticals Inc has a 52-week low of $3.39 and a 52-week high of $11.35. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.24 and a current ratio of 6.24. The firm has a market cap of $198.34 million, a price-to-earnings ratio of -2.58 and a beta of 2.61.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.03. Syndax Pharmaceuticals had a negative net margin of 4,539.55% and a negative return on equity of 107.48%. The company had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.38 million. As a group, analysts forecast that Syndax Pharmaceuticals Inc will post -1.98 earnings per share for the current fiscal year.
Several brokerages recently commented on SNDX. Zacks Investment Research raised shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a report on Wednesday, May 8th. BTIG Research cut their price target on shares of Syndax Pharmaceuticals to $19.00 and set a “buy” rating for the company in a report on Friday, March 8th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target (down previously from $22.00) on shares of Syndax Pharmaceuticals in a report on Friday, March 8th. They noted that the move was a valuation call. ValuEngine lowered shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Finally, Nomura boosted their price target on shares of Syndax Pharmaceuticals to $16.00 and gave the stock a “buy” rating in a report on Friday, March 8th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Syndax Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $14.61.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.
Read More: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.